(Lung Cancer) Is Tumor-Infiltrating Lymphocyte Therapy Plus Nivolumab Effective?

TIL Therapy Combined with Nivolumab in Anti-PD-1 Resistant NSCLC

• September 14, 2021
• Reading time: 1 minute

On August 12, 2021, Benjamin C. Creelan and colleagues at H. Lee Moffitt Cancer Center & Research Institute published in the medical journal Nature Medicine the efficacy and safety results of a Phase 1 clinical trial evaluating tumor-infiltrating lymphocyte (TIL) therapy combined with the anti-PD-1 antibody nivolumab in patients with advanced non-small cell lung cancer (NSCLC) resistant to anti-PD-1 therapy.

This single-arm Phase 1 trial enrolled patients with anti-PD-1 antibody-resistant NSCLC who had experienced disease progression after first-line nivolumab treatment. Patients received TIL therapy combined with nivolumab. The primary endpoint was safety, and the secondary endpoint was objective response rate (ORR).

Safety results (primary endpoint): The incidence of serious adverse events with TIL therapy plus nivolumab was 17% or below.

Efficacy results (secondary endpoint): Among 13 evaluable patients, 3 patients responded to treatment, tumor shrinkage was confirmed in 11 patients, and 2 achieved complete response, with a duration of 1.5 years.

Based on these Phase 1 results, Benjamin C. Creelan and colleagues concluded that TIL therapy combined with nivolumab was well tolerated in patients with anti-PD-1 resistant advanced NSCLC and may represent a promising new treatment option.

Source: https://www.nature.com/articles/s41591-021-01462-y

Tags: #Immunotherapy #ClinicalTrial

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer